240 related articles for article (PubMed ID: 23835701)
1. Cutaneous leishmaniasis in Switzerland: first experience with species-specific treatment.
Mosimann V; Neumayr A; Hatz C; Blum JA
Infection; 2013 Dec; 41(6):1177-82. PubMed ID: 23835701
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis.
Vélez I; López L; Sánchez X; Mestra L; Rojas C; Rodríguez E
Am J Trop Med Hyg; 2010 Aug; 83(2):351-6. PubMed ID: 20682881
[TBL] [Abstract][Full Text] [Related]
3. Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children.
Rubiano LC; Miranda MC; Muvdi Arenas S; Montero LM; Rodríguez-Barraquer I; Garcerant D; Prager M; Osorio L; Rojas MX; Pérez M; Nicholls RS; Gore Saravia N
J Infect Dis; 2012 Feb; 205(4):684-92. PubMed ID: 22238470
[TBL] [Abstract][Full Text] [Related]
4. Treatment of imported New World cutaneous leishmaniasis in Germany.
Harms G; Scherbaum H; Reiter-Owona I; Stich A; Richter J
Int J Dermatol; 2011 Nov; 50(11):1336-1342. PubMed ID: 22004484
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for therapeutic failure to meglumine antimoniate and miltefosine in adults and children with cutaneous leishmaniasis in Colombia: A cohort study.
Castro MDM; Cossio A; Velasco C; Osorio L
PLoS Negl Trop Dis; 2017 Apr; 11(4):e0005515. PubMed ID: 28379954
[TBL] [Abstract][Full Text] [Related]
6. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran.
Mohebali M; Fotouhi A; Hooshmand B; Zarei Z; Akhoundi B; Rahnema A; Razaghian AR; Kabir MJ; Nadim A
Acta Trop; 2007 Jul; 103(1):33-40. PubMed ID: 17586452
[TBL] [Abstract][Full Text] [Related]
7. Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil.
Chrusciak-Talhari A; Dietze R; Chrusciak Talhari C; da Silva RM; Gadelha Yamashita EP; de Oliveira Penna G; Lima Machado PR; Talhari S
Am J Trop Med Hyg; 2011 Feb; 84(2):255-60. PubMed ID: 21292895
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of New World cutaneous leishmaniasis with a combination of topical paromomycin/methylbenzethonium chloride and injectable meglumine antimonate.
Soto J; Hernandez N; Mejia H; Grogl M; Berman J
Clin Infect Dis; 1995 Jan; 20(1):47-51. PubMed ID: 7727669
[TBL] [Abstract][Full Text] [Related]
9. American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis resistant to meglumine antimoniate, but with good response to pentamidine: a case report.
Pimentel MI; Baptista C; Rubin EF; Vasconcellos Ede C; Lyra MR; Salgueiro Mde M; Saheki MN; Rosalino CM; Madeira Mde F; Silva AF; Confort EM; Schubach Ade O
Rev Soc Bras Med Trop; 2011; 44(2):254-6. PubMed ID: 21552747
[TBL] [Abstract][Full Text] [Related]
10. Should we continue to indicate meglumine antimoniate as first-line treatment for cutaneous leishmaniasis in Tunisia.
Mlika RB; Hamida MB; Hammami H; Jannet SB; Badri T; Fenniche S; Mokhtar I
Dermatol Ther; 2012; 25(6):615-8. PubMed ID: 23210761
[TBL] [Abstract][Full Text] [Related]
11. Ex vivo host and parasite response to antileishmanial drugs and immunomodulators.
Gonzalez-Fajardo L; Fernández OL; McMahon-Pratt D; Saravia NG
PLoS Negl Trop Dis; 2015 May; 9(5):e0003820. PubMed ID: 26024228
[TBL] [Abstract][Full Text] [Related]
12. Systemic Meglumine Antimoniate in Cutaneous Leishmaniasis of Children: Clinical and Laboratory Complications.
Layegh P; Khademi Z; Afzal Aghaee M; Moghiman T
J Pediatric Infect Dis Soc; 2015 Dec; 4(4):356-8. PubMed ID: 26582874
[TBL] [Abstract][Full Text] [Related]
13. Comparison of
Özbilgin A; Çavuş İ; Kaya T; Yıldırım A; Harman M
Turkiye Parazitol Derg; 2020 Mar; 44(1):12-16. PubMed ID: 32212583
[TBL] [Abstract][Full Text] [Related]
14. Combined suboptimal schedules of topical paromomycin, meglumine antimoniate and miltefosine to treat experimental infection caused by Leishmania (Viannia) braziliensis.
de Morais-Teixeira E; Aguiar MG; Soares de Souza Lima B; Ferreira LA; Rabello A
J Antimicrob Chemother; 2015 Dec; 70(12):3283-90. PubMed ID: 26346991
[TBL] [Abstract][Full Text] [Related]
15. Comparison Of Efficacy Of Miltefosine Versus Meglumine Antimonate In The Treatment Of Cutaneous Leishmaniasis.
Mohammad N; Sagheer F; Paracha MM; Khan AQ; Naseem S; Wasim M
J Ayub Med Coll Abbottabad; 2022; 34(4):849-853. PubMed ID: 36566412
[TBL] [Abstract][Full Text] [Related]
16. Genotypic profiles of Leishmania (Viannia) braziliensis strains from cutaneous leishmaniasis patients and their relationship with the response to meglumine antimoniate treatment: a pilot study.
Gagini T; de Oliveira Schubach A; de Fatima Madeira M; Maria Valete-Rosalino C; Fernandes Pimentel MI; da Silva Pacheco R
Parasite; 2017; 24():34. PubMed ID: 28959938
[TBL] [Abstract][Full Text] [Related]
17. [Miltefosine versus meglumine antimoniate in the treatment of mucosal leishmaniasis].
Garcia Bustos MF; Barrio A; Parodi C; Beckar J; Moreno S; Basombrio MA
Medicina (B Aires); 2014; 74(5):371-7. PubMed ID: 25347898
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis.
Berger BA; Cossio A; Saravia NG; Castro MDM; Prada S; Bartlett AH; Pho MT
PLoS Negl Trop Dis; 2017 Apr; 11(4):e0005459. PubMed ID: 28384261
[TBL] [Abstract][Full Text] [Related]
19. Liposomal amphotericin B in travelers with cutaneous and muco-cutaneous leishmaniasis: Not a panacea.
Guery R; Henry B; Martin-Blondel G; Rouzaud C; Cordoliani F; Harms G; Gangneux JP; Foulet F; Bourrat E; Baccard M; Morizot G; Consigny PH; Berry A; Blum J; Lortholary O; Buffet P;
PLoS Negl Trop Dis; 2017 Nov; 11(11):e0006094. PubMed ID: 29155816
[TBL] [Abstract][Full Text] [Related]
20. Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis.
Arevalo J; Ramirez L; Adaui V; Zimic M; Tulliano G; Miranda-Verástegui C; Lazo M; Loayza-Muro R; De Doncker S; Maurer A; Chappuis F; Dujardin JC; Llanos-Cuentas A
J Infect Dis; 2007 Jun; 195(12):1846-51. PubMed ID: 17492601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
